PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
8935.00 - 9125.00
6347.00 - 10045.00
380.0K / 335.9K (Avg.)
23.15 | 391.09
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
4.88%
Revenue growth of 4.88% vs. zero growth in Healthcare. Walter Schloss might still want to see if it can translate into profits.
5.75%
Gross profit growth of 5.75% while Healthcare median is zero. Walter Schloss might see a slight advantage that could be built upon.
12.67%
EBIT growth of 12.67% while Healthcare median is zero. Walter Schloss would see a marginal edge that could be expanded upon.
12.67%
Operating income growth exceeding 1.5x Healthcare median of 0.07%. Joel Greenblatt would see if unique processes drive exceptional profitability.
-3.27%
Negative net income growth while Healthcare median is 0.00%. Seth Klarman would investigate factors dragging net income down.
-3.27%
Negative EPS growth while Healthcare median is 0.00%. Seth Klarman would explore whether share dilution or profit declines are to blame.
-3.27%
Negative diluted EPS growth while Healthcare median is 0.00%. Seth Klarman would look for the cause: weakened profitability or heavier share issuance.
-0.00%
Share reduction while Healthcare median is 0.24%. Seth Klarman would see a relative advantage if others are diluting.
-0.00%
Diluted share reduction while Healthcare median is 0.16%. Seth Klarman would see an advantage if others are still diluting.
-100.00%
Dividend cuts while Healthcare median is 0.00%. Seth Klarman would see if others maintain or grow payouts, highlighting a relative weakness.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
25.34%
10Y CAGR of 25.34% while Healthcare median is zero. Walter Schloss might see a slight advantage that can compound over very long horizons.
48.58%
5Y CAGR of 48.58% while Healthcare is zero. Walter Schloss might see a slight improvement that could compound if momentum builds.
25.30%
3Y CAGR of 25.30% while Healthcare median is zero. Walter Schloss might see a modest improvement overshadowing the broader sector’s stagnation.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
9.18%
Net income/share CAGR exceeding 1.5x Healthcare median of 1.29% over a decade. Joel Greenblatt might see a standout compounder of earnings.
39.74%
5Y net income/share CAGR > 1.5x Healthcare median of 0.45%. Joel Greenblatt might see superior mid-term capital allocation or product strength.
28.36%
3Y net income/share CAGR of 28.36% while Healthcare median is zero. Walter Schloss might see a small advantage that can be scaled further.
151.08%
Equity/share CAGR exceeding 1.5x Healthcare median of 48.64% over 10 years. Joel Greenblatt would see if a high ROE underlies this compounding advantage.
101.86%
5Y equity/share CAGR > 1.5x Healthcare median of 29.26%. Joel Greenblatt sees a possible ROE advantage or fewer share issuances boosting book value.
50.02%
3Y equity/share CAGR > 1.5x Healthcare median of 19.73%. Joel Greenblatt sees strong short-term returns on equity fueling net worth growth.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
35.35%
AR growth of 35.35% while Healthcare median is zero. Walter Schloss checks if the difference points to new credit strategy or stronger sales push.
-2.20%
Decreasing inventory while Healthcare is rising. Seth Klarman might see an efficiency advantage or possibly a sign of weaker sales future.
2.82%
We expand assets while Healthcare is negative. Peter Lynch sees a possible advantage if expansions align with profitable markets or a recovering cycle.
2.57%
Positive BV/share change while Healthcare median is negative. Peter Lynch finds a strong advantage vs. peers failing to expand equity.
-57.60%
Debt is shrinking while Healthcare median is rising. Seth Klarman might see an advantage if growth remains possible.
No Data
No Data available this quarter, please select a different quarter.
83.47%
SG&A growth of 83.47% while Healthcare median is zero. Walter Schloss sees a modest overhead increase needing revenue justification.